Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors
Open Access
- 20 November 2025
- journal article
- practice guideline
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (3) , 802-809
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Interleukin-17A Inhibitors in Patients with Psoriasis and Tuberculosis Infection: A 2-Year Prospective Study on Safety Without Preventive TreatmentDermatology and Therapy, 2024
- A Propensity Score-Matched Study on the Changes of TB Status and TB-IGRA Values in Patients with Psoriasis with Latent TB Receiving SecukinumabDermatology and Therapy, 2023
- Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative ReviewAdvances in Therapy, 2023
- Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infectionClinical Rheumatology, 2023
- Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension StudyArthritis & Rheumatology, 2022
- Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension StudyArthritis & Rheumatology, 2022
- Treatment with secukinumab for plaque psoriasis in patients with infectious comorbidities and latent tuberculosis: A multi‐case report analysisClinical Case Reports, 2022
- Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing SpondylitisJAMA Dermatology, 2021
- Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque PsoriasisJAMA Dermatology, 2020
- The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis PathogenesisClinical Reviews in Allergy & Immunology, 2018